quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:01:00·178d
PRRelease
Aldeyra Therapeutics Inc. logo

Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules

ALDX· Aldeyra Therapeutics Inc.
Health Care
Original source

Companies

  • ALDX
    Aldeyra Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Mar 18UpdateH.C. Wainwright$2.00
  • Apr 3UpdateOppenheimer$10.00
  • Apr 2UpdateH.C. Wainwright$10.00
  • Apr 27UpdateH.C. Wainwright$15.00
  • Dec 21UpdateCitigroup$21.00
  • Dec 21UpdateSVB Leerink$15.00

Related

  • SEC3d
    Aldeyra Therapeutics Inc. filed SEC Form 8-K: Leadership Update
  • SEC22d
    SEC Form 8-K filed by Aldeyra Therapeutics Inc.
  • INSIDER23d
    SEC Form 4 filed by Brady Todd C
  • SEC28d
    Amendment: SEC Form SCHEDULE 13G/A filed by Aldeyra Therapeutics Inc.
  • INSIDER34d
    SEC Form 4 filed by Douglas Richard
  • INSIDER35d
    SEC Form 4 filed by Alfieri Michael
  • ANALYST37d
    Aldeyra Therapeutics downgraded by H.C. Wainwright with a new price target
  • SEC38d
    Aldeyra Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022